References
- Helmy YA, Fawzy M, Elaswad A, et al. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9(4):1225.
- Abi-Habib M Millions had Risen out of poverty. Coronavirus is pulling them back. The New York Times [Internet]. 2020 Apr 30 [cited 2020 Jun 2]. Available from: https://www.nytimes.com/2020/04/30/world/asia/coronavirus-poverty-unemployment.html
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
- Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr 1;8(4):420–422.
- Murthy S, Gomersall CD, Fowler RA. Care for critically Ill patients with COVID-19. JAMA. 2020;323(15):1499–1500.
- U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment [Internet]. FDA. 2020 [cited 2020 Jun 6]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
- Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study [published correction appears in Eur Respir J. Eur Respir J. 2020 Sep 24;56(3):2000524. 55(5).
- Antinori S, Cossu MV, Ridolfo AL, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020 May 11;158:104899.
- Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
- Hasan SS, Kow CS, Merchant H. Is it worth the wait? Should chloroquine or hydroxychloroquine be allowed for immediate use in CoViD-19? Bri J Pharmacy. 2020;5(1):745.
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589.
- Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. Preprint. medRxiv. 2020; 2020.03.17.20037432.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
- Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
- Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
- Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020;382(24):2327–2336.
- Pasquini Z, Montalti R, Temperoni C, et al. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. J Antimicrob Chemother. 2020;75(11):3359–3365.
- Aiswarya D, Arumugam V, Dineshkumar T, et al. Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance. Kidney Int Rep. 2021;6(3):586–593.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
- Beigel JH B, Tomashek KM, Dodd LE. Remdesivir for the treatment of covid-19 - preliminary report. Reply. N Engl J Med. 2020;383(10):994.
- Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795–807.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826.
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383(19):1827–1837.
- Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057.
- WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
- Hillaker E, Belfer JJ, Bondici A, et al. Delayed initiation of remdesivir in a COVID-19-positive patient. Pharmacotherapy. 2020;40(6):592–598.
- Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303.
- Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–430.
- National Institutes of Health. Lopinavir/Ritonavir and Other HIV Protease Inhibitors | coronavirus Disease COVID-19 [Internet]. COVID-19 Treatment Guidelines. 2020 [cited 2020 Jun 3]. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/lopinavir-ritonavir-and-other-hiv-protease-inhibitors/
- Wu J, Wu B, Lai T. Compassionate use of remdesivir in Covid-19. N Engl J Med. 2020;382(25):e101.
- Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the polish association of epidemiologists and infectiologists as of march 31 2020. Pol Arch Intern Med. 2020;130(4):352–357.
- Gilead Sciences. Gilead sciences statement on access to remdesivir outside of clinical trials [Internet]. 2020 [cited 2020 Jun 4]. Available from: https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials
- European Medicines Agency. First COVID-19 treatment recommended for EU authorisation [Internet]. European Medicines Agency. 2020 [cited 2020 Jul 17]. Available from: https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation
- Pharmaceutical Technology. Japanese regulator approves Gilead’s remdesivir to treat Covid-19 [Internet]. 2020 [cited 2020 Jun 5]. Available from: https://www.pharmaceutical-technology.com/news/gilead-remdesivir-approval-japan/
- Ministers Department of Health. Australia’s first COVID-19 treatment approved [Internet]. Australian Government Department of Health. 2020 [cited 2020 Jul 17]. Available from: https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/australias-first-covid-19-treatment-approved
- European Medicines Agency. EMA starts rolling review of remdesivir for COVID-19 [Internet]. European Medicines Agency. 2020 [cited 2020 Jun 5]. Available from: https://www.ema.europa.eu/en/news/ema-starts-rolling-review-remdesivir-covid-19
- Pharmaceutical Technology. UK grants early access to Gilead’s remdesivir for Covid-19 [Internet]. 2020 [cited 2020 Jun 5]. Available from: https://www.pharmaceutical-technology.com/news/uk-remdesivir-covid-19/
- Pharmaceutical Technology. Singapore approves Gilead’s remdesivir to treat Covid-19 [Internet]. Pharmaceutical Technology. 2020 [cited 2020 Jul 17]. Available from: https://www.pharmaceutical-technology.com/news/singapore-remdesivir-approval/
- U.S. Food and Drug Administration. Remdesivir by gilead sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment. FDA [Internet]. 2020 Jun 15 [cited 2020 Jul 17]. Available from: https://www.fda.gov/safety/medical-product-safety-information/remdesivir-gilead-sciences-fda-warns-newly-discovered-potential-drug-interaction-may-reduce
- Gilead Sciences. Remdesivir Clinical Trials [Internet]. 2020 [cited 2020 Jun 6]. Available from: https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials
- FIERCE Pharma. Researchers develop dry powder remdesivir to strike COVID-19 where it counts [Internet]. FiercePharma. 2020 [cited 2021 Jan 20]. Available from: https://www.fiercepharma.com/drug-delivery/using-inhaled-remdesivir-and-a-repurposed-tapeworm-med-to-hit-covid-19-where-it